Business Context and Reporting Period
Company: Biomerica, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Six and three months ended November 30, 2009 (Fiscal Year 2010).
Business Overview: Biomerica manufactures and sells diagnostic products, primarily for the detection of infectious diseases. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended Nov 30, 2009 | Three Months Ended Nov 30, 2009 |
|---|---|---|
| Net Sales | $2,248,401 | $1,099,880 |
| Gross Profit | $592,954 | $216,517 |
| Gross Margin | 26.4% | 19.7% |
| Operating Loss | $(301,480) | $(306,199) |
| Net Loss | $(297,772) | $(305,706) |
| Diluted EPS | $(0.04) | $(0.05) |
| Cash and Equivalents (Nov 30, 2009) | $1,403,397 | |
| Working Capital (Nov 30, 2009) | $3,264,443 | |
| Net Cash Used in Operating Activities | $(26,278) | N/A (Six-month data only) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 2.9% ($66,519) for the six months and 1.8% ($20,695) for the quarter compared to the prior year. This was driven by lower sales of the EZ Detect product and reduced sales to a specific distributor in Europe.
- Margin Compression: Gross margin deteriorated significantly. Cost of sales increased from 62.6% of sales in the prior year to 73.6% for the six months ended Nov 30, 2009. For the quarter, cost of sales rose from 70.3% to 80.3%.
- Profitability: The company reported a net loss of $297,772 for the six months ended Nov 30, 2009, compared to a net income of $37,796 in the same period of the prior year.
- Expense Increases:
- Cost of Sales: Increased due to a facility move which caused idle facility costs, temporary production decreases, and higher wages. Approximately $19,000 in material costs for product replacements was also included.
- SG&A: Increased by 15.4% for the quarter, primarily due to non-recurring moving expenses of approximately $84,000.
- R&D: Increased 57.4% for the six months due to higher material and supply costs for new product development.
- Interest: Interest expense decreased due to lower interest rates and smaller debt balances.
Outlook, Risks, and Unusual Items
- Facility Move Impact: The company's recent relocation significantly impacted operations, leading to idle facility costs and reduced production levels at the end of the quarter, which negatively affected margins.
- Capital Expenditures: Purchases of property and equipment increased to $250,041 for the six months ended Nov 30, 2009 (vs. $60,033 prior year), primarily for equipment and leasehold improvements at the new location.
- Subsequent Events: At the annual meeting on December 10, 2009, a proposed stock option plan was not approved by shareholders.
- Risk Factors: Management highlights risks including macroeconomic downturns, dependence on international distributors, raw material availability, regulatory compliance, and competition from larger entities.
- Liquidity: The company maintains positive working capital of $3.26 million and cash of $1.4 million. Operating cash flow improved significantly compared to the prior year, using only $26,278 in cash versus $84,472 in the prior period.
Investor Verification Checklist
- Margin Recovery: Verify if the gross margin deterioration (down to ~26%) is a temporary anomaly due to the facility move or a structural issue.
- Facility Move Completion: Confirm the status of the new facility and whether production levels have normalized to pre-move capacity.
- European Distributor: Assess the long-term impact of the reduced sales to the specific European distributor mentioned in the MD&A.
- Inventory Valuation: Review the inventory reserve of $105,000 and the composition of work-in-process ($846,000) given the production slowdown.
- Capital Needs: Evaluate if the current cash position ($1.4M) is sufficient to fund ongoing R&D and operations without further dilution, especially given the failed stock option plan vote.